MENLO THERAPEUTICS INC's ticker is MNLO and the CUSIP is 586858102. A total of 59 filers reported holding MENLO THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $283,000 | -55.0% | 105,500 | -22.1% | 0.01% | -25.0% |
| Q4 2019 | $629,000 | +5.5% | 135,500 | +1.8% | 0.01% | 0.0% |
| Q3 2019 | $596,000 | -24.5% | 133,100 | +1.1% | 0.01% | -20.0% |
| Q2 2019 | $789,000 | -23.7% | 131,700 | 0.0% | 0.01% | -23.1% |
| Q1 2019 | $1,034,000 | +100.8% | 131,700 | +5.4% | 0.01% | +85.7% |
| Q4 2018 | $515,000 | -58.1% | 124,900 | 0.0% | 0.01% | -41.7% |
| Q3 2018 | $1,230,000 | – | 124,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 1,461,552 | $11,473,000 | 9.29% |
| Vivo Capital, LLC | 4,011,236 | $31,488,000 | 3.14% |
| DAFNA Capital Management LLC | 600,030 | $4,710,000 | 2.03% |
| GREAT POINT PARTNERS LLC | 2,057,027 | $16,148,000 | 1.60% |
| MANGROVE PARTNERS IM, LLC | 561,138 | $4,405,000 | 0.59% |
| Alambic Investment Management, L.P. | 66,996 | $526,000 | 0.22% |
| FIRST MANHATTAN CO. LLC. | 2,256,903 | $17,716,000 | 0.10% |
| Orbimed Advisors | 633,920 | $4,976,000 | 0.08% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 198,451 | $1,558,000 | 0.06% |
| Baker Brothers Advisors | 700,000 | $5,495,000 | 0.04% |